Comparison 3. Antiviral versus placebo/no treatment.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.1 Improvement in vertigo frequency at 3 to < 6 months	1	23	Risk Ratio (M‐H, Random, 95% CI)	1.38 [0.28, 6.75]
3.2 Change in vertigo frequency at 3 to < 6 months	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
3.3 Disease‐specific health‐related quality of life at 3 to < 6 months	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
3.4 Change in hearing at 3 to < 6 months	1	16	Mean Difference (IV, Random, 95% CI)	4.30 [‐13.94, 22.54]